3 results
Approved WMOCompleted
The primary study objective is to assess the proportion of patients who remain within the IGF-I age adjusted normal limits with pasireotide LAR (60 mg) monotherapy, after 24 weeks of treatment.Secondary study objectives are assessment of the…
Approved WMOCompleted
To investigate safety and tolerability as well as the induced immune response upon MesoPher/mitazalimab combination therapy in metastasized pancreatic disease after (modified) FOLFIRINOX.
Approved WMOCompleted
Primary Objective: To establish that ACT guided heparinization results in safe and optimal anticoagulation during open AAA repair. We hypothesize that ACT guided heparinization will result in a decrease of thrombo-embolic complications, without a…